Motilal Oswal Financial Services stamped a 20% upside call on consumer titan Titan Company and formulation specialist Rubicon Research, wagering that cash-rich market leaders will outpace broader equity benchmarks as corporate earnings stabilize.
Both stocks carry distinct structural advantages in a market wrestling with selective mid-cap valuations. Siddhartha Khemka, Head of Research for Wealth Management at Motilal Oswal, set a ₹5,700 target price on Titan and a ₹2,100 target on Rubicon Research. The thesis hinges on operational execution over multiple quarters rather than short-term market noise.
Titan trades at an expensive multiple of roughly 55 times projected fiscal 2027-28 earnings. The valuation commands respect. Khemka argued that Tata Group's flagship lifestyle retailer justifies that price tag through entrenched retail dominance, sustained store additions, and expanding operating margins. A softer-than-expected jewellery quarter failed to rattle the brokerage's outlook.
Instead, order books tell a different story. Same-store sales growth held firm. Higher-margin studded jewellery grabbed a larger share of overall ticket sizes, while the company's watches division delivered stable volume expansions. These underlying business metrics cushion retail volatility.
Rubicon Research presented a textbook operational breakout. The drugmaker expanded quarterly revenue by 40%, while earnings before interest, taxes, depreciation, and amortization jumped 53%. Net profit surged 68%.
Cash conversion followed operating leverage. Motilal Oswal raised its forward earnings estimates for Rubicon, pointing to deep research pipelines and the upcoming commercialization of three new manufacturing plants to feed supply agreements across regulated export territories.
| Company | Target Price | Implied Upside | Core Operational Catalyst | Valuation / Growth Metric |
|---|---|---|---|---|
| Titan Company | ₹5,700 | ~20% | Studded jewellery mix, watches division | 55x FY28 Price-to-Earnings |
| Rubicon Research | ₹2,100 | ~20% | 3 plant commercializations, R&D yield | Revenue +40%, PAT +68% |
Big money is stepping back in. Foreign institutional investors absorbed nearly ₹35,000 crore in Indian equities across five consecutive trading sessions. Meanwhile, Brent crude cooled below $100 a barrel, easing imported inflation pressures on corporate input bills and retail consumer wallets.
Khemka expects large-cap bellwethers to anchor the next leg of Dalal Street's advance. Mid- and small-cap opportunities remain selective, tied strictly to companies demonstrating immediate capacity expansion and margin resilience.